Illumina customers questioned by EU regulator on impact of Grail acquisition
Illumina customers have been asked questions about the implications of the company’s $8 billion swoop for cancer-testing company Grail as part of the EU investigation of the deal, MLex has learned....To view the full article, register now.
Already a subscriber? Click here to view full article